N-(2,3-dihydroxypropyl)succinic acid monoamide | 173144-53-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-(2,3-dihydroxypropyl)succinic acid monoamide
• 英文别名: Dhs-OH；4-(2,3-Dihydroxypropylamino)-4-oxobutanoic acid
• CAS: 173144-53-1
• 化学式: C₇H₁₃NO₅
• 分子量: 191.184
• InChiKey: NPNFLZNIXAJGPS-UHFFFAOYSA-N

物化性质

• 沸点：
  599.8±50.0 °C(Predicted)
• 密度：
  1.365±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  107
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(2,3-dihydroxypropyl)succinic acid monoamide 、 4,4'-双甲氧基三苯甲基氯 在 吡啶 作用下， 生成 4-[[3-[Bis(4-methoxyphenyl)-phenylmethoxy]-2-hydroxypropyl]amino]-4-oxobutanoic acid
  参考文献：
  名称：

  [EN] CONJUGATES AND PREPARATION AND USE THEREOF
  [FR] CONJUGUÉS ET PRÉPARATION ET UTILISATION ASSOCIÉES

  摘要：

  揭示了一种用于与活性剂形成共轭物的化合物，例如具有由公式（321）表示的结构的寡核苷酸，并且相应的共轭物。该共轭物可以特异性地靶向肝细胞，因此有效地解决了与体内寡核苷酸药物传递相关的问题，并且在保持传递的寡核苷酸高稳定性的同时具有低毒性和出色的传递效率。

  公开号：

  WO2019128611A1
• 作为产物：
  描述：

  丁二酸酐 、 3-氨基-1,2-丙二醇 在 三乙胺 作用下， 以 异丙醇 为溶剂， 反应 0.5h， 生成 N-(2,3-dihydroxypropyl)succinic acid monoamide
  参考文献：
  名称：

  TLR2配体Pam2Cys的激动剂活性的结构要求

  摘要：

  合成脂肽已显示出作为引发细胞和体液免疫的疫苗策略的巨大潜力。使用的最有效的脂质部分之一是S- [2,3-双（棕榈酰氧基）丙基]半胱氨酸（Pam2Cys）。Pam2Cys通过参与Toll样受体2（TLR 2）结合并激活树突状细胞。在这项研究中，我们通过改变核心结构S的三个结构元素，研究了Pam2Cys激动剂活性的结构要求。-（2，3-二羟丙基）-半胱氨酸，即（1）半胱氨酸残基的α-氨基；（2）半胱氨酸残基的硫原子；和（3）2，3-二羟丙基部分。制备了四个新颖的​​Pam2Cys类似物，并将这些类似物中的每一个掺入疫苗构建物中并检查了免疫原性。我们的结果表明（1）脱氨性肽疫苗的效力受到的影响最小（2）硫原子被酰胺键取代会导致生物活性显着降低（3）脱氨性和同时用酰胺键取代硫会显着降低两种类似物的生物活性（4），其中硫原子被酰胺键取代，而该类似物含有1，3-二羟丙基部分显示出比含有2，3-二羟丙基

  DOI：

  10.1007/s00726-009-0463-0

文献信息

• Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof
  申请人：SUZHOU RIBO LIFE SCIENCE CO., LTD.

  公开号：US11492620B2

  公开（公告）日：2022-11-08

  Provided is a modified double-stranded oligonucleotide, in which the sense strand comprises a nucleotide sequence 1, the anti-sense strand comprises a nucleotide sequence 2, the nucleotide sequences 1 and 2 are both 19 nucleotides in length, and in the direction from 5′ end to 3′ end, nucleotides at positions 7, 8 and 9 of the nucleotide sequence 1 and nucleotides at positions 2, 6, 14 and 16 of the nucleotide sequence 2 are all fluoro-modified nucleotides, and each nucleotide at other positions is independently one of non-fluoro-modified nucleotides. Further provided are a pharmaceutical composition and a conjugate comprising the oligonucleotide, and pharmaceutical use thereof.

  提供了一种修饰的双链寡核苷酸，其中有义链包括核苷酸序列1，反义链包括核苷酸序列2，核苷酸序列1和2的长度均为19个核苷酸，方向从5′端到3′端、核苷酸序列1的第7、8和9位的核苷酸和核苷酸序列2的第2、6、14和16位的核苷酸都是氟修饰的核苷酸，其他位置的每个核苷酸独立地是非氟修饰的核苷酸之一。进一步提供了包含寡核苷酸的药物组合物和共轭物及其药物用途。
• NUCLEIC ACID, COMPOSITION AND CONJUGATE COMPRISING THE SAME, AND PREPARATION METHOD AND USE THEREOF
  申请人：SUZHOU RIBO LIFE SCIENCE CO., LTD.

  公开号：US20210277400A1

  公开（公告）日：2021-09-09

  Provided are an siRNA for inhibiting expression of a Hepatitis B virus gene, and a pharmaceutical composition and conjugate containing the siRNA. Each nucleotide in the siRNA is an independently modified or unmodified nucleotide; the siRNA comprises a sense strand and an antisense strand; the sense strand comprises a nucleotide sequence A; the length of the nucleotide sequence A is the same as that of a nucleotide sequence as shown in SEQ ID NO: 1, and the number of the nucleotide differences is not more than three; the antisense strand comprises a nucleotide sequence B; and the length of the nucleotide sequence B is the same as that of a nucleotide sequence as shown in SEQ ID NO: 2, and number of nucleotide differences is not more than three.
• DOUBLE-STRANDED OLIGONUCLEOTIDE, COMPOSITION AND CONJUGATE COMPRISING DOUBLE-STRANDED OLIGONUCLEOTIDE, PREPARATION METHOD THEREOF AND USE THEREOF
  申请人：SUZHOU RIBO LIFE SCIENCE CO., LTD.

  公开号：US20220049249A1

  公开（公告）日：2022-02-17

  Provided is a modified double-stranded oligonucleotide, in which the sense strand comprises a nucleotide sequence 1, the anti-sense strand comprises a nucleotide sequence 2, the nucleotide sequences 1 and 2 are both 19 nucleotides in length, and in the direction from 5′ end to 3′ end, nucleotides at positions 7, 8 and 9 of the nucleotide sequence 1 and nucleotides at positions 2, 6, 14 and 16 of the nucleotide sequence 2 are all fluoro-modified nucleotides, and each nucleotide at other positions is independently one of non-fluoro-modified nucleotides. Further provided are a pharmaceutical composition and a conjugate comprising the oligonucleotide, and pharmaceutical use thereof.